I first heard about CRISPR from a RadioLab podcast a couple of years ago. It is a genetic engineering technology that has scientists around the world excited. Using CRISPR technology, scientists can cut out and replace specific parts of DNA. While I can think of several frightening uses of this technology, the potentials for good are impressive. We are on the verge of curing genetic diseases.
Intellia Therapeutics (NASDAQ: NTLA) is one company that is focusing their research on CRISPR. They are using a technology called CRISPR/Cas9 to edit genetic sequences. Among their current research is a possible cure for Hepatitis B, a disease that kills hundreds of thousands of people each year.
If you have a large, diverse portfolio of stocks as I do, you can safely add NTLA into your mix. It is a biotech company that is not currently making a profit. That makes it a risky investment that could either go out of business or gain massive returns over the next few years.
You can also invest in CRISPR technology itself. There are three big players in the space: Editas Medicine (EDIT), Crispr Therapeutics (CRISPR) and Intellia Therapeutics (NTLA). If you believe the technology has a big future, why not invest in all three companies? That way even if two of them go bankrupt, if the third one quadruples in value you will still make money.
The official website for Intellia Therapeutics is www.intelliatx.com.
I purchased a position of NTLA on June 23 for $14.55 a share. I purchased another position July 7 for $16.76 a share. I think the stock is a good buy under $18 per share. I plan to hold NTLA for at least one year. If you’re investing in all three CRISPR stocks (EDIT, CRISPR, and NTLA), plan on holding them for three years or longer. That should give the technology enough time to play out.
Disclaimer and disclosures: As with all investment information, you should do your own research and/or consult with a professional before making investment decisions. Remember, it’s your money. The information provided here represents my personal opinions. I own shares of NTLA and EDIT.